Cargando…

Cardiovascular disease prevalence in type 2 diabetes – an analysis of a large German statutory health insurance database

BACKGROUND: The aim of this study was to determine the prevalence of cardiovascular disease in persons with type 2 diabetes mellitus (T2D) in Germany. METHODS: A claims database with an age- and sex-stratified sample of nearly 4 million individuals insured within the German statutory health system w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabler, Maximilian, Geier, Silke, Mayerhoff, Lukas, Rathmann, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874491/
https://www.ncbi.nlm.nih.gov/pubmed/33563256
http://dx.doi.org/10.1186/s12889-021-10381-z
Descripción
Sumario:BACKGROUND: The aim of this study was to determine the prevalence of cardiovascular disease in persons with type 2 diabetes mellitus (T2D) in Germany. METHODS: A claims database with an age- and sex-stratified sample of nearly 4 million individuals insured within the German statutory health system was used. All patients aged ≥18 years with T2D documented between 1 January 2015 and 31 December 2015 and complete retrospective documentation of ≥5 years (continuous enrollment in the German statutory health system) before 2015 were selected based on a validated algorithm. Cardiovascular disease (CVD) events were identified based on ICD-10 and OPS codes according to a previous clinical study (EMPA-REG OUTCOME trial). RESULTS: The prevalence of T2D in Germany in 2015 was 9.9% (n = 324,708). Using a narrow definition of CVD, the 6-year observation period prevalence of CVD was estimated as 46.7% [95% CI: 46.52%;46.86%]. Applying a wider CVD definition, the proportion of T2D patients who showed a history of CVD was 57.1% [95% CI: 56.9%;57.24%]. The prevalence of CVD in patients with T2D ranged from 36.3 to 57.1%, depending on the observation period and definition of CVD. CONCLUSIONS: The results underline the need for a population-based registration of cardiovascular complications in T2D.